James D. Thomas
Known title: Chief Accounting OfficerCIK: 0001784360
Associated companies
Transaction History
| NUS | ▲ Buy | Grant | 114,706 | $0 | 3/6/2026 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 28,602 | $247K | 2/26/2026 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 11,725 | $98K | 2/15/2026 | View on chart |
| NUS | ▲ Buy | Grant | 9,847 | $0 | 2/10/2026 | View on chart |
| NUS | ▲ Buy | Grant | 47,436 | $0 | 2/10/2026 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 915 | $8K | 8/1/2025 | View on chart |
| NUS | ▲ Buy | Grant | 71,152 | $0 | 2/26/2025 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 10,856 | $82K | 2/15/2025 | View on chart |
| NUS | ▲ Buy | Grant | 4,055 | $0 | 2/12/2025 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 1,638 | $18K | 8/1/2024 | View on chart |
| NUS | ▲ Buy | Grant | 43,444 | $0 | 2/27/2024 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 4,719 | $65K | 2/15/2024 | View on chart |
| NUS | ▲ Buy | Grant | 663 | $0 | 2/13/2024 | View on chart |
| NUS | ▲ Buy | Grant | 1,638 | $0 | 2/13/2024 | View on chart |
| NUS | ▲ Buy | Grant | 8,328 | $0 | 7/26/2023 | View on chart |
| NUS | ▲ Buy | Grant | 6,360 | $0 | 3/31/2023 | View on chart |
| NUS | ▼ Sell | Open Market | 2,829 | $116K | 2/23/2023 | View on chart |
| NUS | ▲ Buy | Grant | 9,330 | $0 | 2/22/2023 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 1,295 | $59K | 2/15/2023 | View on chart |
| NUS | ▼ Sell | Open Market | 1,602 | $63K | 9/7/2022 | View on chart |
| NUS | ▲ Buy | Grant | 8,557 | $0 | 2/25/2022 | View on chart |
| NUS | ▼ Sell | Tax Withholding | 799 | $40K | 2/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nu Skin: Turnaround Narrative Gains Attention
A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.
Nu Skin: Turnaround Narrative Gains Attention. A recent analysis suggests that Nu Skin's potential turnaround may be in its early stages. The company currently trades at a low price with a high dividend yield, while the stock is testing a key support level. This context highlights the contrast between current market sentiment and the long-term outlook discussed in the news.